Redeye returns with an updated view on Nanologica following its Q1 report. Sales and EBIT was softer than our estimates, but the company reported its highest quarterly chromatography sales to date. We somewhat lower our base case.

Read more and download the Research Update.
 
Follow companies at Redeye to receive the latest equity research within Life Science and Technology.
 
This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/

Attachments

Nanologica Q1 2024 - Mixed start of the year

© Modular Finance, source Nordic Press Releases